These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2858154)
1. Disodium azodisalicylate. American College of Gastroenterology Committee on FDA-Related Matters. Levinson RA Am J Gastroenterol; 1985 Mar; 80(3):203-5. PubMed ID: 2858154 [TBL] [Abstract][Full Text] [Related]
2. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Habal FM; Greenberg GR Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391 [TBL] [Abstract][Full Text] [Related]
3. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats. Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431 [TBL] [Abstract][Full Text] [Related]
4. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Lauritsen K; Hansen J; Bytzer P; Bukhave K; Rask-Madsen J Gut; 1984 Nov; 25(11):1271-8. PubMed ID: 6149981 [TBL] [Abstract][Full Text] [Related]
5. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Lauritsen K; Hansen J; Ryde M; Rask-Madsen J Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704 [TBL] [Abstract][Full Text] [Related]
6. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H; Munakata A; Yoshida Y J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870 [TBL] [Abstract][Full Text] [Related]
8. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. Cohen HD; Das KM J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699 [TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine. Das KM Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795 [TBL] [Abstract][Full Text] [Related]
10. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518 [TBL] [Abstract][Full Text] [Related]
11. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee. September 15-16, 1988. The ACG Committee on FDA-related matters. American College of Gastroenterology. Stern WR Am J Gastroenterol; 1989 Apr; 84(4):351-4. PubMed ID: 2494882 [No Abstract] [Full Text] [Related]
12. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine. Kimura I; Kawasaki M; Matsuda A; Kataoka M; Kokurba Y Arzneimittelforschung; 1998 Dec; 48(12):1163-7. PubMed ID: 9893931 [TBL] [Abstract][Full Text] [Related]
14. Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate. Sullivan SN J Clin Gastroenterol; 1987 Aug; 9(4):461-3. PubMed ID: 2888803 [TBL] [Abstract][Full Text] [Related]
15. Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo. Goerg KJ; Wanitschke R; Gabbert H; Breiling J; Franke M; Meyer zum Büschenfelde KH Digestion; 1987; 37(2):79-87. PubMed ID: 2887473 [TBL] [Abstract][Full Text] [Related]
16. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Sandborn WJ Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Klotz U Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155 [TBL] [Abstract][Full Text] [Related]
18. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. Andreoli A; Spinella S; Levenstein S; Prantera C Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759 [TBL] [Abstract][Full Text] [Related]
19. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Friedman LS; Richter JM; Kirkham SE; DeMonaco HJ; May RJ Am J Gastroenterol; 1986 Jun; 81(6):412-8. PubMed ID: 3518408 [TBL] [Abstract][Full Text] [Related]
20. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Marshall JK; Irvine EJ Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]